

Amanda E D Van Swearingen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4448700/publications.pdf>

Version: 2024-02-01

47
papers

852
citations

516710

16
h-index

501196

28
g-index

50
all docs

50
docs citations

50
times ranked

1775
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 1371-1383.	8.2	126
2	Effects of Acute Tryptophan Depletion on Brain Serotonin Function and Concentrations of Dopamine and Norepinephrine in C57BL/6J and BALB/cj Mice. <i>PLoS ONE</i> , 2012, 7, e35916.	2.5	69
3	Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i> -Mutated and <i>BRCA</i> ^{WT} Wild-Type Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 920-930.	4.1	62
4	Sex differences in novelty- and psychostimulant-induced behaviors of C57BL/6 mice. <i>Psychopharmacology</i> , 2013, 225, 707-718.	3.1	56
5	HER2 ⁺ positive breast cancer brain metastasis: A new and exciting landscape. <i>Cancer Reports</i> , 2022, 5, e1274.	1.4	54
6	Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes. <i>Nature Communications</i> , 2019, 10, 4192.	12.8	52
7	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. <i>Cancer Research</i> , 2020, 80, 4314-4323.	0.9	51
8	High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. <i>Science Advances</i> , 2020, 6, eaba5542.	10.3	48
9	Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 1469-1480.	1.2	42
10	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 637-648.	2.5	40
11	Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. <i>Neuro-Oncology</i> , 2017, 19, 1481-1493.	1.2	32
12	Experimentally Dissecting the Origins of Peroxiredoxin Catalysis. <i>Antioxidants and Redox Signaling</i> , 2018, 28, 521-536.	5.4	25
13	Individual differences in psychostimulant responses of female rats are associated with ovarian hormones and dopamine neuroanatomy. <i>Neuropharmacology</i> , 2012, 62, 2267-2277.	4.1	24
14	Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT [®] nanoparticle formulation against non-small-cell lung cancer brain metastases. <i>Nanomedicine</i> , 2016, 11, 1947-1955.	3.3	23
15	A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking. <i>Cancer Research</i> , 2020, 80, 4972-4985.	0.9	23
16	Estradiol replacement enhances cocaine-stimulated locomotion in female C57BL/6 mice through estrogen receptor alpha. <i>Neuropharmacology</i> , 2013, 72, 236-249.	4.1	17
17	Dietary manipulation of serotonergic and dopaminergic function in C57BL/6J mice with amino acid depletion mixtures. <i>Journal of Neural Transmission</i> , 2014, 121, 153-162.	2.8	16
18	Breast cancer brain metastases: evidence for neuronal-like adaptation in a ^{breast-to-brain} transition?. <i>Breast Cancer Research</i> , 2014, 16, 304.	5.0	13

#	ARTICLE	IF	CITATIONS
19	Simplified dietary acute tryptophan depletion: effects of a novel amino acid mixture on the neurochemistry of C57BL/6J mice. Food and Nutrition Research, 2015, 59, 27424.	2.6	11
20	Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. , 2022, 10, e003427.		11
21	Advances in the management of breast cancer brain metastases. Neuro-Oncology Advances, 2021, 3, v63-v74.	0.7	10
22	Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models. Neuro-Oncology Advances, 2019, 1, vdz005.	0.7	9
23	Multidisciplinary Management of Breast Cancer Brain Metastases. Oncology, 2016, 30, 923-33.	0.5	8
24	The Promise of Immunotherapy for Breast Cancer Brain Metastases. Current Breast Cancer Reports, 2019, 11, 241-247.	1.0	7
25	Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. ACS Pharmacology and Translational Science, 2021, 4, 703-712.	4.9	7
26	Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery. Frontiers in Oncology, 0, 12, .	2.8	4
27	Receptor discordance in breast cancer brain metastases: when knowledge is power. Neuro-Oncology, 2020, 22, 1060-1061.	1.2	3
28	Preparation and Characterization of Poly(2-oxazoline) Micelles for the Solubilization and Delivery of Water Insoluble Drugs. Bio-protocol, 2021, 11, e3959.	0.4	3
29	Abstract 5449A: PI3K and MEK inhibition in intracranial triple negative breast cancer: Efficacy of BKM120 and AZD6244 in preclinical mouse models. , 2014, , .		1
30	Abstract 2579: Combination therapy with MEK inhibition is efficacious in intracranial triple negative breast cancer models. , 2015, , .		1
31	Abstract 2813: Efficacy and pharmacokinetics of niraparib in <i>BRCA</i>-mutant and wild-type intracranial triple negative breast cancer murine models. Cancer Research, 2018, 78, 2813-2813.	0.9	1
32	Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis. Oncology, 2014, 28, 579, 584-5.	0.5	1
33	A Need for More Molecular Profiling in Brain Metastases. Frontiers in Oncology, 2021, 11, 785064.	2.8	1
34	Brain metastasis as first and only metastatic relapse site portends poor outcomes in patients with advanced HER2+ breast cancer.. Journal of Clinical Oncology, 2022, 40, 1045-1045.	1.6	1
35	Specific Residues in Peroxiredoxins Promote Peroxide Reactivity Through Effects on Cysteine pKa, Transition State Stabilization and Oligomerization. Free Radical Biology and Medicine, 2012, 53, S151.	2.9	0
36	52. BrMPANEL: A PUBLIC RESOURCE OF ORGANOTROPIC CELL LINES. Neuro-Oncology Advances, 2020, 2, ii10-ii11.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Preparation of an Orthotopic, Syngeneic Model of Lung Adenocarcinoma and the Testing of the Antitumor Efficacy of Poly(2-oxazoline) Formulation of Chemo-and Immunotherapeutic Agents. Bio-protocol, 2021, 11, e3953.	0.4	0
38	Abstract PD15-01: Snord67 promotes lymph node metastasis through U6-mediated alternative splicing in breast cancer. , 2021, , .		0
39	Effect of type and timing of systemic therapy on risk of radiation necrosis in patients with HER2+ breast cancer brain metastases.. Journal of Clinical Oncology, 2021, 39, e14002-e14002.	1.6	0
40	Impact of extracranial disease status on survival after initial central nervous system (CNS) involvement and radiation therapy in HER2+ breast cancer brain metastases (BCBM).. Journal of Clinical Oncology, 2021, 39, 1041-1041.	1.6	0
41	An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM).. Journal of Clinical Oncology, 2021, 39, 9521-9521.	1.6	0
42	OTHR-10. Diverse survival outcomes of HER2+ Breast Cancer Brain Metastases (BrCBM) presenting with isolated brain relapse compared to those with concurrent extracranial disease. Neuro-Oncology Advances, 2021, 3, iii16-iii16.	0.7	0
43	OTHR-14. An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM). Neuro-Oncology Advances, 2021, 3, iii17-iii17.	0.7	0
44	Abstract 3867: Combined PI3K and AURKA inhibition are efficacious in triple-negative breast cancer models. , 2016, , .		0
45	Abstract A03: Several rational combination kinase inhibitor treatments identified by synthetic lethality screens are efficacious in intracranial triple negative breast cancer models. , 2017, , .		0
46	Abstract B32: Silencing of oncogenic KRAS by a mutant-favoring short interfering RNA. , 2020, , .		0
47	258â€¦Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. , 2020, , .		0